Sponsor:
GlaxoSmithKline
Code:
NCT06613698
Conditions
Liver Diseases, Alcoholic
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Interventions
GSK4532990
Placebo
Brief summary:
Conditions
Liver Diseases, Alcoholic
Study ID
NCT06613698
Start date
Sep 27, 2024
Status verified date
Jul, 2026
Completion date
Mar 7, 2028
Anticipated
Primary completion date
Nov 26, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Enrollment
393 participants
Anticipated
Intervention Model
Sequential
Primary purpose
Treatment
Arms
experimental: GSK4532990 Dose 1
experimental: GSK4532990 Dose 2
experimental: GSK4532990 Dose 3
experimental: GSK4532990 Dose 4
placebo comparator: Placebo
Interventions
GSK4532990
Placebo
Primary outcome measure
Central contacts
Locations
GSK Investigational Site
Recruiting
Chandler, Arizona, United States, 85224
Contacts
Principal Investigator:
Anita Kohli
GSK Investigational Site
Recruiting
Phoenix, Arizona, United States, 85006
Contacts
Principal Investigator:
Moises Nevah Rubin
GSK Investigational Site
Recruiting
Tucson, Arizona, United States, 85712
Contacts
Principal Investigator:
Aimee Bachelier
GSK Investigational Site
Recruiting
Tucson, Arizona, United States, 85715
Contacts
Principal Investigator:
Fadi Deeb
GSK Investigational Site
Recruiting
Coronado, California, United States, 92118
Contacts
Principal Investigator:
Tarek Hassanein
GSK Investigational Site
Recruiting
Lancaster, California, United States, 93534
Contacts
Principal Investigator:
Jatinder Pruthi
GSK Investigational Site
Recruiting
Los Angeles, California, United States, 90033
Contacts
Principal Investigator:
Norah Terrault
GSK Investigational Site
Recruiting
Los Angeles, California, United States, 90048
Contacts
Principal Investigator:
Hyunseok Kim
GSK Investigational Site
Recruiting
Pasadena, California, United States, 91105
Contacts
Principal Investigator:
Edward Mena
GSK Investigational Site
Recruiting
Sacramento, California, United States, 95817
Contacts
Principal Investigator:
Vikrant Rachakonda
GSK Investigational Site
Recruiting
Brandon, Florida, United States, 33511
Contacts
Principal Investigator:
Patrick Weston
GSK Investigational Site
Recruiting
Miami, Florida, United States, 33173
Contacts
Principal Investigator:
Barbara Moscoso
GSK Investigational Site
Recruiting
Miami Lakes, Florida, United States, 33016
Contacts
Principal Investigator:
William Sanchez
GSK Investigational Site
Recruiting
Atlanta, Georgia, United States, 30309
Contacts
Principal Investigator:
Lance Stein
GSK Investigational Site
Recruiting
Indianapolis, Indiana, United States, 46202
Contacts
Principal Investigator:
Raj Vuppalanchi
GSK Investigational Site
Recruiting
Topeka, Kansas, United States, 66606
Contacts
Principal Investigator:
Shekhar Challa
GSK Investigational Site
Recruiting
Marrero, Louisiana, United States, 70072
Contacts
Principal Investigator:
Gary Reiss
GSK Investigational Site
Recruiting
Detroit, Michigan, United States, 48202
Contacts
Principal Investigator:
Syed-Mohammed Jafri
GSK Investigational Site
Recruiting
Las Vegas, Nevada, United States, 89106
Contacts
Principal Investigator:
Elliot Shin
GSK Investigational Site
Recruiting
New York, New York, United States, 10029
Contacts
Principal Investigator:
Frances Lee
GSK Investigational Site
Recruiting
Chapel Hill, North Carolina, United States, 27514
Contacts
Principal Investigator:
Hersh Shroff
GSK Investigational Site
Recruiting
Cleveland, Ohio, United States, 44195
Contacts
Principal Investigator:
Srinivasan Dasarathy
GSK Investigational Site
Recruiting
Philadelphia, Pennsylvania, United States, 19014
Contacts
Principal Investigator:
K. Rajender Reddy
GSK Investigational Site
Recruiting
Hermitage, Tennessee, United States, 37076
Contacts
Principal Investigator:
Donald Lazas Jr
GSK Investigational Site
Recruiting
Arlington, Texas, United States, 76012
Contacts
Principal Investigator:
Reem Ghalib
GSK Investigational Site
Recruiting
Austin, Texas, United States, 78757
Contacts
Principal Investigator:
Rohit Puskoor
GSK Investigational Site
Recruiting
Dallas, Texas, United States, 75203
Contacts
Principal Investigator:
Mangesh Pagadala
GSK Investigational Site
Recruiting
Dallas, Texas, United States, 75390-8565
Contacts
Principal Investigator:
Thomas Kerr
GSK Investigational Site
Recruiting
Fort Worth, Texas, United States, 76104
Contacts
Principal Investigator:
Thomas Cotter
GSK Investigational Site
Recruiting
Georgetown, Texas, United States, 78626
Contacts
Principal Investigator:
Rohit Puskoor
GSK Investigational Site
Recruiting
San Antonio, Texas, United States, 78215
Contacts
Principal Investigator:
Eric Lawitz
GSK Investigational Site
Recruiting
Richmond, Virginia, United States, 23219
Contacts
Principal Investigator:
Amon Asgharpour
GSK Investigational Site
Recruiting
Richmond, Virginia, United States, 23249
Contacts
Principal Investigator:
Jasmohan Bajaj
GSK Investigational Site
Recruiting
Calgary, Alberta, Canada, T2N 4Z6
Contacts
Principal Investigator:
Henry Nguyen
GSK Investigational Site
Recruiting
New Westminster, British Columbia, Canada, V3L 3W4
Contacts
Principal Investigator:
Steven Cheuk-Fung Pi
GSK Investigational Site
Recruiting
Vancouver, British Columbia, Canada, V6Z 2K5
Contacts
Principal Investigator:
Alnoor Ramji
GSK Investigational Site
Recruiting
London, Ontario, Canada, N6A 5A5
Contacts
Principal Investigator:
Mohammad Qasim Khan
GSK Investigational Site
Recruiting
Toronto, Ontario, Canada, M1S 4T7
Contacts
Principal Investigator:
Gerald Chan
GSK Investigational Site
Recruiting
Toronto, Ontario, Canada, M5G 2C4
Contacts
Principal Investigator:
Jordan Feld
GSK Investigational Site
Recruiting
Montreal, Quebec, Canada, H2X 0A9
Contacts
Principal Investigator:
Julian Hercun
GSK Investigational Site
Recruiting
Terrebonne, Quebec, Canada, J6X 4P7
Contacts
Principal Investigator:
Yves Robitaille
Sponsor
GlaxoSmithKline
Last update posted
Aug 3, 2026
Last verified
Jul, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by GlaxoSmithKline on 2026-08-03.